LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

Home・Stock List・Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings Inc (Class A)

Closed

SectorHealthcare

4.13 -3.73

Buy Sell

Overview

Share price change

24h

Current

Min

4.09

Max

4.15

Key metrics
By Trading Economics
Income	36M -3.7M
Sales	16M 66M
EPS	0.01
Profit margin	-5.67
Employees	435
EBITDA	57M 15M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+16.14% upside

Dividends
By Dow Jones
Next Earnings	10 Aug 2026

Market Stats
By TradingEconomics
Market Cap	350M 1.7B
Previous open	7.86
Previous close	4.13

News Sentiment

By Acuity

50%

136 / 345 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

2.02 / 2.115 Support & Resistance

Maravai LifeSciences Holdings Inc (Class A) Chart

Past performance is not a reliable indicator of future results.

Related News

17 May 2026, 23:53 UTC

Acquisitions, Mergers, Takeovers

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15 May 2026, 22:47 UTC

Hot Stocks

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 May 2026, 22:16 UTC

Acquisitions, Mergers, Takeovers

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 May 2026, 22:00 UTC

Major Market Movers

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 May 2026, 18:09 UTC

Major Market Movers

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17 May 2026, 23:50 UTC

Market Talk

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17 May 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

17 May 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17 May 2026, 23:36 UTC

Market Talk

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17 May 2026, 23:07 UTC

Acquisitions, Mergers, Takeovers

UOB: Transactions Part of Group's Capital Reallocation Strategy

17 May 2026, 23:06 UTC

Acquisitions, Mergers, Takeovers

UOB: Share Sale Agreements Entered With Singland Properties

17 May 2026, 23:05 UTC

Acquisitions, Mergers, Takeovers

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17 May 2026, 22:31 UTC

Acquisitions, Mergers, Takeovers

Prudential PLC to Fund Stake Acquisition via Internal Resources

17 May 2026, 22:31 UTC

Acquisitions, Mergers, Takeovers

Prudential PLC to Acquire Stake for $389 Million

17 May 2026, 22:30 UTC

Acquisitions, Mergers, Takeovers

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16 May 2026, 16:27 UTC

Acquisitions, Mergers, Takeovers

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 May 2026, 15:26 UTC

Acquisitions, Mergers, Takeovers

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16 May 2026, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 May 2026, 22:17 UTC

Acquisitions, Mergers, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 May 2026, 21:59 UTC

Acquisitions, Mergers, Takeovers

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 May 2026, 21:50 UTC

Acquisitions, Mergers, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 May 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 May 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 May 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 May 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 May 2026, 20:19 UTC

Hot Stocks

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 May 2026, 19:41 UTC

Acquisitions, Mergers, Takeovers

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 May 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 May 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 May 2026, 18:35 UTC

Earnings

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Peer Comparison

Price change

Maravai LifeSciences Holdings Inc (Class A) Forecast

Price Target

By TipRanks

16.14% upside

12 Months Forecast

Average 4.82 USD 16.14%

High 6 USD

Low 3 USD

Based on 7 Wall Street analysts offering 12 month price targets forMaravai LifeSciences Holdings Inc (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Maravai LifeSciences Holdings Inc (Class A) - Dist in the past 3 months.

Technical Score

By Trading Central

2.02 / 2.115Support & Resistance

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There are no events.

Sentiment

By Acuity

136 / 345 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.